thenoyltrifluoroacetone has been researched along with rosiglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| He, X; Jiang, Q; Jiang, W; Li, Z; Liu, Z; Lu, X; Shao, H; Si, S; Xu, Y; Yang, Y; Zhang, H; Zhao, B; Zheng, Z | 1 |
2 other study(ies) available for thenoyltrifluoroacetone and rosiglitazone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Two thiophenes compounds are partial peroxisome proliferator-activated receptor α/γ dual agonists.
Topics: Animals; Cell Culture Techniques; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Genes, Reporter; Hepatocytes; Humans; Hypoglycemic Agents; Mice; Molecular Targeted Therapy; Plasmids; PPAR alpha; PPAR gamma; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfoxides; Thenoyltrifluoroacetone; Thiazolidinediones; Thiophenes | 2011 |